Author: admin

  • Angel Di Maria, Pierre-Emerick Aubameyang & 20 under-the-radar summer transfers you might have missed

    Angel Di Maria, Pierre-Emerick Aubameyang & 20 under-the-radar summer transfers you might have missed

    While certain deals have grabbed the headlines, some big names have quietly been on the move and some shrewd business has been done

    It has been another record-breaking summer of spending in the transfer market, with Premier League’s outlay alone incredibly surpassing the £2.5 billion ($3.4bn) mark. And there is still the ever-frantic deadline day to come.

    Plenty of big names have been on the move, with Trent Alexander-Arnold heading to Real Madrid, Florian Wirtz swapping Bayer Leverkusen for Liverpool in a huge £116 million ($156m) deal and Viktor Gyokeres choosing Arsenal after a drawn-out transfer saga at Sporting CP.

    But what about the deals that have gone under the radar but have helped to make up those astonishing numbers? In a record-breaking summer, here are 20 transfers you might have missed…

    Continue Reading

  • Apple vs banana vs lemon: Science ranks the healthiest fruit for your diet |

    Apple vs banana vs lemon: Science ranks the healthiest fruit for your diet |

    For decades, apples and bananas have been regarded as the go-to fruits for a healthy diet. Rich in fiber, vitamins, and minerals, they are staples in many people’s daily meals. However, recent research from William Paterson University has revealed a surprising contender for the title of most nutritious fruit: the lemon. Evaluating 41 different fruits based on nutritional density, vitamin content, antioxidants, and overall health benefits, the study found that lemon ranks at the top. Small but powerful, lemons are fully equipped with nutrients that support immunity, digestion, heart health, and overall wellness, making them a true nutritional powerhouse.

    Apple vs banana vs lemon: Which fruit is truly the healthiest

    For years, apples and bananas have been considered staples in health-conscious diets. Celebrated for their fiber, vitamin C, potassium, and versatility, these fruits have long been go-to options for maintaining a balanced diet. However, a study from William Paterson University has shifted the spotlight to a lesser-celebrated citrus fruit, the lemon. The findings were published in the journal Preventing Chronic Disease by the Centers for Disease Control and Prevention (CDC). Evaluating 41 fruits on various health metrics, researchers found that lemon ranks highest in overall nutritional value.

    Discover the Health Benefits of the Rainbow Diet

    The study assessed fruits based on nutritional density, vitamin content, antioxidants, and other health-promoting compounds. Despite its small size and tangy flavor, the lemon outperformed many popular fruits due to its combination of vitamin C, soluble fiber, flavonoids, and diverse plant compounds. These nutrients are essential for supporting immunity, aiding digestion, and reducing the risk of cardiovascular problems. In other words, the lemon is a fruit fully equipped to provide multiple health benefits in a single serving.

    How lemon benefits your body

    What sets lemon apart is not just its impressive vitamin profile but also the way it interacts with the body. Though naturally acidic, lemon has an alkalizing effect once metabolized, helping maintain a healthier pH balance. This effect can improve gut health, enhance digestion, and even support better nutrient absorption.Additionally, the flavonoids in lemons contribute to long-term heart health by helping lower blood pressure and cholesterol. Coupled with its soluble fiber content, lemon can stabilize blood sugar levels and promote the growth of beneficial gut bacteria. This combination of effects makes lemon a fruit uniquely equipped to support overall wellness, far beyond the benefits of apples or bananas alone.

    More than just juice: Full potential of lemons

    The study also emphasised the often-overlooked benefits of lemon peel. Rich in limonene, an essential oil with antimicrobial and potential anti-cancer properties, lemon peel is a nutritional powerhouse. Unlike thinner-skinned citrus fruits, the thick peel of lemons contains a higher concentration of these beneficial compounds. Grating lemon peel into meals not only enhances flavor but also adds significant health advantages.Moreover, the versatility of lemons allows them to be incorporated into a variety of dishes, from drinks to desserts. Flavonoids in lemon may reduce inflammation, support cardiovascular health, and contribute to a stronger immune system. Combined with its fiber content, lemon is a fruit fully equipped to support digestive health, regulate blood sugar, and promote overall metabolic balance.

    Everyday ways to include lemons in your diet

    Even for those who find lemons too sour to eat directly, there are simple ways to make them part of a daily routine. A popular method is adding lemon juice to warm water, sometimes with a dash of honey, as a morning ritual to kick-start digestion. Lemon juice can also enhance the flavor and nutritional value of salads, soups, rice dishes, and smoothies. Incorporating lemon zest adds a subtle citrus aroma along with antioxidants and essential plant compounds.Professionals advise caution when consuming concentrated lemon juice, especially on an empty stomach. Its acidity can harm tooth enamel or irritate the stomach in sensitive individuals. Diluting lemon juice with water is recommended, and anyone with digestive conditions should consult a healthcare professional before making lemons a regular dietary staple. With mindful use, lemons can be fully equipped to enhance both taste and health in everyday meals.Disclaimer: This article is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider regarding any medical condition or lifestyle change.Also Read: Is avocado harming you: 5 types of people who should avoid eating avocado


    Continue Reading

  • Women’s Rugby World Cup needs jeopardy to stay in Monday morning conversations | Women’s Rugby World Cup 2025

    Women’s Rugby World Cup needs jeopardy to stay in Monday morning conversations | Women’s Rugby World Cup 2025

    After all these years of asking for more, it’s churlish to complain when the Women’s Rugby World Cup delivered so much in one weekend. England’s victory pulled in two-and-half million prime time viewers on the BBC, 85,000 fans turned out across the four grounds, including a record-breaking 42,000 crowd in Sunderland, five hat-tricks, four packed fan zones, free concerts, and all those fireworks. It had almost everything anyone could have wanted. Almost. The one thing missing was a tight finish. The closest of the eight games was settled by three tries and change.

    The success of the World Cup isn’t just going to be measured by what happens on the weekends, but in the days in between them. World Rugby wants people to be talking about this tournament when they go into work on Monday morning. And for that to happen it needs some jeopardy.

    There were 72 tries in eight matches altogether, but 66 of them were by the winning team. England scored 11, so did Australia and Canada. South Africa scored 10. New Zealand eight. Blowouts happen in the pool stages of every Rugby World Cup: there were a bunch of one-sided matches in the men’s tournament two years ago, when France beat Namibia 96-0, New Zealand scored 96 against Italy and Ireland defeated Romania 82-8. The difference this time was in what happened in between. The matches that we hoped would be close turned out anything but, with Scotland beating Wales 38-8 and France beating Italy 24-0.

    Which didn’t surprise anyone who regularly watches women’s rugby, but maybe requires some explaining to the huge new audience who are only just discovering it.

    “The numbers don’t always tell the full story,” said World Rugby’s director of women’s rugby, Sally Horrox, when she was asked about it this week. Horrox argues that 49% of women’s rugby fans have come to it in the past two years regardless of how uneven the standard. These scorelines don’t necessarily stop the games from being entertaining. And she’s right, the Red Roses’ victory was as good as a one-sided game gets. No one at the stadium felt it suffered from being so predictable. Like the competition director, Yvonne Nolan, said, there was a lot of “fast, free-flowing rugby”, and plenty to admire in the way the losing teams played.

    But it’s true, too, that no amount of fireworks or free concerts can disguise the gaps between some of these teams. Women’s rugby needs the enthusiastic support of the media as it grows; its lack of visibility is, World Rugby argues, the biggest obstacle to its success. So there are good reasons why a lot of what is written and said about the women’s game tends to gloss over the obvious imbalances between the teams. The irony is that it’s a sign a sport has matured that everyone involved is able to be honest about what everyone’s watching, instead of celebrating the simple fact that so many people are.

    The Samoa team rely on donations to cover lost income from their regular jobs. Photograph: Molly Darlington/World Rugby/Getty Images

    To their credit, Horrox and Nolan are both too smart to pretend anything else. They don’t shy away from speaking about the lopsided results, which are inevitable given the uneven pace of development in women’s game around the world. “These teams,” as Nolan says, “are all at different stages of their journey.” Women’s rugby is growing so quickly that the gaps between the teams are actually wider now than they were during the first tournament, back in 1991 (when only one match ended with a 50-point margin) because a handful of sides, and England in particular, have raced so far ahead.

    This Saturday, a Red Roses side, who have the benefit of all the expert coaching, medical support and sport science the Rugby Football Union can provide and who, because the country has one of the two professional domestic leagues in the world, are paid to play and train seven days a week, take on Samoa, who don’t even have national contracts, and whose team include a full-time property manager, police officer and primary school teacher, who all had to rely on donations to cover the lost income they have suffered by missing work to compete in England.

    Which invites the question of which is the better achievement, an overwhelming victory for the professionals or an honourable defeat for the amateurs? If they’re honest, the Red Roses will know that given their pedigree and the resources at their disposal, they made too many basic mistakes even when they beat the USA by 62 points. And that, too, may be the result of the fact that they have had so few close matches in recent years that they have been able to get away with being sloppy.

    skip past newsletter promotion

    World Rugby is doing what it can to help narrow the gap. It has provided all the smaller teams with access to a pool of nine specialist coaches, who work across set pieces, skills, and strength and conditioning, Alain Rolland has been brought in to work with them on how to reduce their penalty counts.

    But they can’t cover everything. Even Canada, who are one of the strongest teams in this tournament, had to crowdfund the last $1m of the $3.2m they needed to compete.

    But in the long term, a lot of this will come down to the hard work of widespread structural change, the small steps forward in between the tournaments, as well as the great leaps made during them.

    Continue Reading

  • Hamzah Sheeraz Carries Kronk-Like Power

    Hamzah Sheeraz Carries Kronk-Like Power

    Andy Lee believes Hamzah Sheeraz, the man dubbed “The British Tommy Hearns,” would have fit right in at the Kronk Gym due to his “shocking” power.

    England’s Sheeraz linked up with Lee earlier this year in the wake of his disappointing draw with WBC middleweight champ Carlos Adames on February 22 at ANB Arena in Riyadh, Saudi Arabia. The new relationship paid immediate dividends as Sheeraz crushed Edgar Berlanga inside five rounds July 12 in Queens, New York – just shy of five months after the Adames fight.

    It was the perfect start to life under Lee for Sheeraz, who moved to 22-0-1 (18 KOs) and within touching distance of a fight with Canelo Alvarez as a result of the victory.

    Although the Berlanga victory came at the end of his first camp in Dublin under Lee, the highly rated coach was not willing to take any credit for the win. Lee suggested that it was Sheeraz’s inherent qualities that secured it.

    Lee, who trains other noted punchers like Joseph Parker and Ben Whittaker, admitted that the first time he took Sheeraz on the pads it surprised him.

    “His punching power is truly shocking,” Lee told The Ring. “Hamzah can punch like hell. It really took me by surprise. His left hand is … the only way I can describe it is shocking when he hits you on the pads.

    “And then when it comes to sparring, I see it every time because these guys get in the ring with all these ideas and then the first jab lands and you see their expression change immediately.”

    On the Berlanga victory, which included two knockdowns in the fourth round before the finish came in the fifth, Lee added, “I don’t think you saw any of the real stuff we did in training.

    “And I think the stuff that knocked Berlanga out, Hamzah always did that. He could always put his hands up and go forward and dig in.”

    It was Sheeraz’s promoter, Frank Warren, who first offered the practically unknown youngster professional terms back in 2017, who labelled him “The British Tommy Hearns” due to his tall, wiry frame, long levers and concussive power.

    Lee trained under the late Emanuel Steward and spent many years at the Kronk Gym in Detroit, where Hearns made his name. He is therefore well placed to comment on Warren’s suggestion.

    The Irishman, a former WBO middleweight champion, said, “It’s an obvious comparison just because of the size and the height and the power.

    “But it’s also the attitude … Just wanting to just hurt somebody. Hamzah would have fitted in alright at the Kronk. He would have been perfect in the basement.”

    Sheeraz is not yet back in the gym and it is not clear when he will fight again. He has been strongly linked to a showdown with Alvarez in 2026 should the Mexican superstar successfully navigate his super fight with Terence Crawford on September 13. There is also the chance that Sheeraz will look to box once more in the interim.

    But Lee thinks the real improvement will begin in their next camp, now that Sheeraz has adapted to the training methods properly.

    “Once he comes back,” Lee said, “it will probably take a couple of weeks of building back to where we were and where we left off. Then we’ll have the luxury of working on some of the finer points. We’ve kind of grasped the essence of it now. He just needs to know the basics and then he’s going to get the more flashy stuff, I guess.

    “Before he came here, I didn’t really study him much, to be honest with you. I just knew he was coming and thought I could have a positive impact. But just listening to him and hearing all the stories and how he trains, he’s been through the trenches.”

    Continue Reading

  • Uptake of cervical cancer screening and its associated factors in Africa: an umbrella review of systematic reviews and meta-analyses | BMC Public Health

    Uptake of cervical cancer screening and its associated factors in Africa: an umbrella review of systematic reviews and meta-analyses | BMC Public Health

    Systematic reviews and meta-analyses (SRMAs) are essential tools for addressing clinical and epidemiological questions. However, when multiple related questions within a specific topic need to be synthesized, umbrella reviews offer a practical and comprehensive approach by consolidating evidence from multiple SRMAs. This umbrella review is the first to assess cervical cancer screening uptake and its associated factors among eligible women in Africa, based on findings from 11 SRMAs. The pooled prevalence of screening utilization was found to be 19% (95% CI: 12–25%), with substantial variability across studies, ranging from 8.11 to 41%. Subgroup analyses indicated that factors such as publication year, sample size, and HIV status contributed to this heterogeneity. Notably, key determinants of screening uptake included knowledge of cervical cancer screening, perceived susceptibility to the disease, and formal education. Women with higher levels of knowledge, greater perceived risk, and formal education were more likely to utilize screening services.

    The observed screening rate of 19% aligns with those reported in other low- and middle-income countries, such as Saudi Arabia [30] and Nepal [31] where similar barriers—limited awareness, cultural stigma, and restricted access to healthcare—impede utilization. These findings highlight the persistent challenges in increasing screening coverage in resource-limited settings and underscore the need for context-specific interventions to enhance awareness and accessibility. To provide a more comprehensive and balanced interpretation of our findings, we have incorporated a regional comparison, drawing on evidence from studies conducted in Europe, America, Asia, and the Middle East. This broader perspective allows us to contextualize our results within global patterns and highlights both regional similarities and disparities, thereby aligning with the regional analysis framework of our study. Compared to our findings, screening uptake is markedly higher in high-income regions: 75.2% in the United States [32], 80.15% in the Western Pacific Region, and 74.66% in the European Region [33]. These higher rates are often attributed to robust healthcare systems, organized national screening programs, and higher levels of health literacy [34]. In contrast, our result is comparable to rates reported in the South-East Asia Region (17.71%) and the Eastern Mediterranean Region (16.99%) [33], and also consistent with figures from the Middle East (18.2%) [30]. Screening coverage in African countries remains lower than global averages [33] and significantly lower than in countries such as Austria [31] Hungary [35] Russia [36] and Germany [37]. This disparity reflects structural challenges such as weak health infrastructure, socio-economic constraints, and insufficient public awareness [38, 39]. Notably, the screening rate observed in our study exceeds that of India [40] where coverage remains as low as 5%. This difference underscores the regional variability that exists even among low-resource settings, potentially reflecting more effective awareness initiatives and greater international support in certain African contexts. Such disparities emphasize the urgent need for targeted interventions in Africa aimed at improving healthcare access, strengthening educational efforts, and addressing socio-cultural barriers to enhance cervical cancer screening uptake.

    This umbrella review, which synthesized evidence from 11 systematic reviews and meta-analyses, identified key factors influencing cervical cancer screening utilization in 9 of the included reviews. These factors include formal education, government employment, adequate knowledge of cervical cancer screening, history of sexually transmitted infections (STIs), perceived susceptibility and severity of the disease, perceived barriers, self-efficacy, receipt of medical advice, favorable attitudes, and perceived benefits of screening.

    Women with formal education were found to have 1.85 times higher screening utilization compared to those without. Education enhances health awareness, facilitates access to and understanding of health information, and improves health literacy. It empowers informed decision-making, encourages proactive health-seeking behavior, and helps overcome cultural and social barriers. Additionally, educated women often enjoy better socioeconomic status, enabling them to afford healthcare and prioritize preventive measures [38]. This finding aligns with studies conducted in Austria [31]. Hungary [35] and India [40] But it is lower than the results from Germany [37] and Russia [41]. The higher rates in Germany and Russia may stem from more comprehensive healthcare systems, widespread screening programs, and effective public health education campaigns that boost screening uptake regardless of educational background.

    Government-employed women are twice as likely to utilize cervical cancer screening compared to their counterparts. This can be attributed to better healthcare access through insurance and workplace programs, financial stability, exposure to health campaigns, supportive workplace policies, and higher education levels that enhance health literacy and proactive health-seeking behavior [42]. This finding aligns with systematic reviews and meta-analyses conducted in Nepal [43] a systematic review and meta-analysis study from Arab countries [30]. However, our finding was lower than a study done in Russia [36] and Spain [44] where higher screening rates among government-employed women are likely due to more robust healthcare access as an employment benefit, effective public health campaigns, and workplace policies promoting preventive care. Cultural factors and greater awareness may also encourage proactive health behaviors. In contrast, a study from Nepal [45] reported higher screening odds among unemployed women, possibly reflecting different healthcare priorities or support mechanisms in that context. Meanwhile, infrastructural challenges and less-developed workplace health initiatives in Africa may limit screening utilization among employed women.

    Women with a history of STDs are 1.7 times more likely to utilize cervical cancer screening compared to those without such a history. This could be attributed to their increased interaction with healthcare services, heightened awareness of reproductive health risks, and the likelihood of receiving recommendations from healthcare providers during STD management to undergo cervical cancer screening [46]. This finding agreed with two independent studies done in Saudi Arabia [30, 47]. and Nepal [45].

    Women with high perceived susceptibility are 1.8 times more likely to undergo cervical cancer screening than their counterparts. This heightened risk awareness, often stemming from health education, personal or family illness experiences, and healthcare provider guidance, motivates preventive action [38]. Our findings align with studies from Jordan [48] Saudi Arabia [30] Iran [49] and Spain [44] highlighting the universal role of perceived susceptibility in promoting screening. Regardless of cultural or geographic differences, recognizing vulnerability, driven by education, counseling, and illness exposure, consistently enhances screening uptake.

    Women who perceive cervical cancer as a serious health threat are twice as likely to utilize screening compared to their counterparts. This heightened sense of severity increases awareness of the disease’s potential consequences, motivating women to seek regular screenings as a preventive measure [50]. Our findings align with studies from Serbia, Nepal, and Saudi Arabia. Still, they are lower than those reported in Serbia [51] Nepal [45] and Saudi Arabia, but are lower than those reported in Germany [37] Russia [36] the SRMA study and cross-sectional study in Europe [52, 53] as well as a global study [33]. These differences may stem from variations in healthcare systems, accessibility, and organized screening programs. Socioeconomic disparities, cultural beliefs, limited awareness campaigns, and financial barriers in our study setting likely contribute to lower screening rates. Methodological differences, lack of insurance coverage, and variations in education and healthcare exposure may also explain the observed disparities.

    Women with low perceived barriers are 2.3 times more likely to utilize cervical cancer screening than those with high barriers. This is likely due to fewer psychological, social, or logistical challenges, improving accessibility and confidence in the screening process. In contrast, high perceived barriers, such as fear, stigma, financial constraints, and lack of awareness, often lead to delays or avoidance of screening. Consistent with behavioral health models, reducing barriers enhances preventive care engagement [54]. Our findings align with studies from Nepal [43] Saudi Arabia [30] Iran [49] Russia [36] and Spain [44] highlighting the role of improved access, affordability, and proximity in encouraging screening uptake. Effective education campaigns, positive healthcare experiences, and supportive social environments boost awareness and normalize screening practices. These consistent results across diverse settings underscore the universal need for accessible services, targeted education, and supportive policies to reduce barriers and promote cervical cancer screening.

    Women with high perceived self-efficacy are twice as likely to undergo cervical cancer screening, as they feel confident in managing their health and overcoming challenges. This aligns with behavioral theories, such as Bandura’s self-efficacy theory, which links confidence in personal abilities to proactive health behaviors. High self-efficacy enables women to navigate barriers, seek resources, and prioritize preventive care [54].

    Our findings are consistent with studies from Nepal [43] a systematic review and meta-analysis study from Arab countries [30] But they are lower than those reported in China [55] and France [56]. These differences may be due to variations in healthcare systems, cultural norms, awareness campaigns, and access to screening services. Higher public health education, extensive insurance coverage, and well-established screening programs in China and France likely enhance self-efficacy and screening rates. In contrast, limited access, cultural stigma, and lower health literacy in the study setting may contribute to the comparatively lower rates.

    Women who receive advice on cervical cancer screening are 1.8 times more likely to utilize screening services, underscoring the critical role of healthcare providers’ counseling in promoting screening uptake. This finding aligns with studies from Japan [57] Italy [58] England [59] France [56] and two independent studies in China [55, 60]. Counseling raises awareness, addresses barriers such as fear and misconceptions, and offers tailored guidance, promoting preventive actions. Evidence from diverse cultural contexts underscores the universal significance of provider-driven advice in fostering health-seeking behaviors [61].

    Women with a favorable attitude toward cervical cancer screening are 1.7 times more likely to utilize screening services than those with an unfavorable attitude. This highlights the impact of positive perceptions and beliefs on health-seeking behavior. Favorable attitudes stem from greater awareness, trust in screening benefits, and reduced fear or stigma, emphasizing the importance of targeted interventions to encourage positive views on cervical cancer prevention [62]. Our findings are consistent with studies from China [60] Italy [58] Nepal [43] Saudi Arabia [30] and Iran [49]. Strengthening awareness campaigns, dispelling misconceptions, and fostering trust in screening services can promote positive attitudes and increase screening uptake.

    Women who recognize the benefits of cervical cancer screening are 1.93 times more likely to utilize screening services than those who do not. This may stem from increased awareness, reduced fears and misconceptions, and a stronger motivation for proactive health-seeking behavior. Understanding these benefits also fosters trust in healthcare systems and may inspire women to promote screening within their communities, creating a supportive environment and encouraging others to participate [63]. Our findings align with studies from Saudi Arabia [30] Iran [49] Japan [57] Germany [37] and a systematic review and meta-analysis study from Arab countries [30]. Strengthening education campaigns to highlight the benefits of screening can enhance awareness and trust, reduce barriers, and foster community advocacy, ultimately improving cervical cancer screening uptake.

    In conclusion, this umbrella review highlights the low cervical cancer screening uptake among eligible women in Africa, with a pooled prevalence of just 25%. Key factors influencing screening utilization include education, employment status, knowledge of cervical cancer, history of STDs, perceived susceptibility and severity, self-efficacy, medical advice, and attitudes toward screening. Despite regional variations, common barriers, such as cultural stigma, limited healthcare access, and low awareness, contribute to this low uptake. Subgroup analyses further emphasize the need for tailored interventions, mainly focusing on education, self-efficacy, and raising awareness of the benefits of screening. To improve screening rates, it is crucial to implement targeted health education programs, enhance access to affordable services, and address cultural and psychological barriers. Policy initiatives should support community-based campaigns, healthcare provider counseling, and organized screening efforts to foster proactive health-seeking behavior and ultimately reduce cervical cancer-related mortality in low-resource African settings.

    Strengths and limitations

    The risk of bias was minimized through a comprehensive search across multiple databases, with four researchers independently selecting studies and a fifth resolving discrepancies. The inclusion of a relatively large number of studies enhances the robustness of the findings. Methodological quality was assessed using the AMSTAR-2 tool, and data overlap among primary studies was carefully reviewed to ensure transparency. While some overlap is inherent in umbrella reviews, it was minimal in this study, as most primary studies were unique to specific systematic reviews.

    However, combining data from multiple meta-analyses may still introduce bias and potentially overestimate the strength of the findings. Moreover, due to the substantial heterogeneity across studies (I² = 100%), the generalizability of the pooled estimates is limited, and the results should be interpreted with caution. Additionally, although this umbrella review incorporated systematic reviews and meta-analyses from different regions of Africa, the majority of the included studies were conducted in Ethiopia. While these studies involved varied populations—including HIV-positive individuals, healthcare professionals, and the general population—the geographic concentration may affect the representativeness of the findings for the entire African continent. Therefore, caution is warranted when interpreting the findings in the context of all African countries.

    Continue Reading

  • India will not ‘bow down’, says trade minister after US tariffs

    India will not ‘bow down’, says trade minister after US tariffs



    A 3D-printed miniature model of US President Donald Trump, the Indian flag and the word “Tariffs” are seen in this illustration taken July 23, 2025. — Reuters 

    India will not “bow down” and instead focus on capturing new markets, trade minister Piyush Goyal said in his first public remarks since Washington imposed steep tariffs on Indian goods.

    The 50% levies on many Indian imports into the United States took effect this week as punishment for New Delhi’s massive purchases of Russian oil, part of US efforts to pressure Moscow into ending its war in Ukraine.

    Since his return to the White House this year, US President Donald Trump has wielded tariffs as a wide-ranging policy tool, with the levies upending global trade.

    Speaking at a construction industry event in New Delhi on Friday, Goyal said India was “always ready if anyone wants to have a free trade agreement with us”.

    But, he added, India “will neither bow down nor ever appear weak”.

    “We will continue to move together and capture new markets.”

    The latest tariffs salvo from Trump has strained US-India ties, with New Delhi earlier criticising the levies as “unfair, unjustified and unreasonable”.

    Trade talks between the two countries have stumbled over agriculture and dairy markets.

    Trump wants greater US access, while Indian Prime Minister Narendra Modi is determined to shield India’s farmers, a huge voter bloc.

    The US was India’s top export destination in 2024, with shipments worth $87.3 billion.

    But analysts have cautioned that a 50% duty is akin to a trade embargo and is likely to harm smaller firms.

    Exporters of textiles, seafood and jewelry have already reported cancelled US orders and losses to rivals such as Bangladesh and Vietnam, raising fears of heavy job cuts.

    Goyal said the government would be coming out with several measures in the coming days to support every sector and boost exports.

    “I can say with confidence that India´s exports this year will exceed 2024-25 numbers,” he said.

    Continue Reading

  • Pooled analysis supports the benefits of vericiguat across a broad range of heart failure patients


    Notes to editor

    This press release accompanies a presentation at ESC Congress 2025.  

    It does not necessarily reflect the opinion of the European Society of Cardiology.  

     

    ESC Press Office
    Tel: +33 6 61 40 18 84   
    Email: press@escardio.org

    Follow European Society of Cardiology News on LinkedIn

    The hashtag for ESC Congress 2025 is #ESCCongress  

    Journalists are invited to become accredited and register here. 

    Check out the ESC Media and Embargo Policy. 

     

    Funding: The study was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and Bayer AG. 

    Disclosures: Professor Butler has received consulting fees from Abbott, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, Cardiorem, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Lexicon, Lilly, LivaNova, Janssen, Medtronic, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor and Zoll; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Novartis, Boehringer Ingelheim-Lilly, AstraZeneca, Impulse Dynamics and Vifor. 

     

    References and notes

    1‘VICTOR: Vericiguat Global Study in Participants with Chronic Heart Failure and VICTORIA: Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction’ presented during HOT LINE 2 on 30 August 2025 at 08:43 to 08:53 in Madrid (Main Auditorium). 

    2Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382:1883–1893. 

    3‘VICTOR: Vericiguat Global Study in Participants with Chronic Heart Failure’ presented during HOT LINE 2 on 30 August 2025 at 08:33 to 08:43 in Madrid (Main Auditorium). 

    4Ezekowitz JA, O’Connor CM, Troughton RW, et al. N-terminal pro-B-type natriuretic peptide and clinical outcomes: Vericiguat Heart Failure with Reduced Ejection Fraction Study. JACC Heart Fail 2020;8: 931–939. 

     

    About ESC Congress 2025 

    It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Madrid and online – from 29 August to 1 September 2025. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.

     

    About the European Society of Cardiology

    The ESC brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.


    Continue Reading

  • Pakistan vs UAE Live Streaming in India: When and where to watch 2nd T20I, date, venue; Check PAK vs UAE probable XIs

    Pakistan vs UAE Live Streaming in India: When and where to watch 2nd T20I, date, venue; Check PAK vs UAE probable XIs

    Having beaten Afghanistan a night ago by 39 runs, Pakistan would like to keep their winning momentum in the ongoing T20I tri-series when the Men in Green take on hosts United Arab Emirates (UAE) in Sharjah on Saturday (August 30). The Pakistan vs UAE match starts on 8:30 PM IST.

    Serving as a preparation for the upcoming Asia cup 2025, Pakistan started on a brighter note with their captain leading from the front with an unbeaten half century against Afghanistan in the tournament opener.

    In bowling, Haris Rauf led the charge with four scalps while the likes of Shaheen Shah Afridi, Mohammad Nawaz and Sufiyan Muqeem accounted for two wickets each. On the other hand, UAE will take confidence from their historic series win over Bangladesh recently to upset Pakistan.

    All the teams in the series will play other teams twice in round robin format before the top two advancing into the final on September 7. Both UAE and Pakistan are in the same group with India and Oman in the Asia Cup 2025.

    Pakistan vs UAE 2nd T20I match details

    Venue: Sharjah Cricket Stadium

    Pakistan vs UAE T20I head-to-head

    Despite Pakistan playing so much cricket in the middle east, the Men in Green have played just a solitary T20I against UAE in the shortest format in 2016. The clash, which was also a part of Asia Cup, was won by Pakistan.

    Pakistan vs UAE predicted playing XIs

    Pakistan: Sahibzada Farhan, Saim Ayub, Fakhar Zaman, Salman Agha (c), Hasan Nawaz, Mohammad Haris (wk), Mohammad Nawaz, Faheem Ashraf, Shaheen Afridi, Haris Rauf, Sufiyan Muqeem

    UAE: Muhammad Zohaib, Muhammad Waseem (c), Alishan Sharafu, Rahul Chopra (wk), Asif Khan, Aryansh Sharma, Ethan D’Souza, Dhruv Parashar, Haider Ali, Muhammad Rohid Khan, Muhammad Farooq

    How to watch Pakistan vs UAE T20I clash in India?

    Unfortunately, the T20I tri-series is not telecasted in India. But still the fans can watch Pakistan vs UAE clash on FanCode app and website on a subscription model.

    Continue Reading

  • Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction

    August 30, 2025 2:45 am ET

    Results from the Phase 3 VICTOR trial and a pooled analysis of the VICTOR and VICTORIA trials were presented today at the ESC Congress 2025 and simultaneously published in The Lancet


    Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results evaluating VERQUVO® (vericiguat) in adult patients with stable chronic heart failure and reduced ejection fraction (HFrEF). The Phase 3 VICTOR trial comparing the efficacy of VERQUVO to placebo in patients with HFrEF without a recent worsening heart failure event treated with guideline-directed medical therapy (GDMT) did not reach statistical significance for its primary endpoint of combined time to first event of cardiovascular death or hospitalization for heart failure. In a separate pre-specified pooled analysis of patient-level data from the complementary Phase 3 VICTOR and VICTORIA trials, VERQUVO reduced the risk of the composite primary endpoint of cardiovascular death or heart failure hospitalization across these patients with a broad range of disease severity. Results from both analyses were presented today at the European Society of Cardiology (ESC) Congress 2025 in a Hot Line session and simultaneously published in The Lancet.

    VERQUVO was initially studied and approved in patients with worsening chronic heart failure and ejection fraction less than 45% following a worsening heart failure event based on the pivotal Phase 3 VICTORIA trial. Participants in the VICTOR trial represented a well-treated group of ambulatory HFrEF patients on GDMT and 47.5% of participants had no history of hospitalization for heart failure. Results showed that VERQUVO did not significantly reduce the risk of the primary composite outcome of time to cardiovascular death or hospitalization for heart failure, which occurred in 18% (n=549/3,053) of patients treated with VERQUVO compared to 19.1% (n=584/3,052) in the placebo group (hazard ratio [HR] 0.93; 95% confidence interval [CI] 0.83-1.04; p=0.22). For the key secondary endpoints, cardiovascular death was numerically lower with VERQUVO (9.6%) compared to placebo (11.3%) (HR 0.83; 95% CI 0.71-0.97) and heart failure hospitalization occurred in 11.4% of patients receiving VERQUVO and 11.9% of patients receiving placebo (HR 0.95; 95% CI 0.82–1.10). The overall safety profile of VERQUVO in the VICTOR trial was consistent with previous clinical trials.

    “By studying patients without recent heart failure hospitalizations, the Phase 3 VICTOR trial expands our understanding of VERQUVO across the full spectrum of chronic heart failure patients with reduced ejection fraction,” said Dr. Joerg Koglin, senior vice president and head of general medicine, global clinical development, Merck Research Laboratories. “Together with the previously communicated results in VICTORIA in patients with worsening chronic heart failure and ejection fraction less than 45% following a worsening heart failure event, the results today provide valuable information and add to our understanding of heart failure and VERQUVO. We are grateful to the patients and investigators for their participation in these studies and remain confident in the role of VERQUVO for its approved indication for patients with HFrEF following a recent heart failure event and with ejection fraction less than 45% based on the pivotal Phase 3 VICTORIA trial.”

    The Phase 3 VICTORIA trial focused exclusively on a population with worsening chronic HFrEF at high risk for cardiovascular mortality and repeated heart failure hospitalizations. In a separate pre-specified pooled analysis across VICTOR and VICTORIA, VERQUVO’s benefit was examined in a large and broad cohort. In this pooled analysis of 11,155 HFrEF patients, VERQUVO showed a statistically significant risk reduction across the primary composite endpoint of cardiovascular death or heart failure hospitalization and its components as secondary endpoints, in a broad spectrum of patients with HFrEF. No new safety signals, beyond those reported in the individual trials, emerged in the pooled analysis.

    “While the VICTOR trial did not meet its primary endpoint, the separate pooled analysis across both VICTOR and VICTORIA did demonstrate a statistically significant reduction in the primary composite endpoint of heart failure hospitalization and cardiovascular deaths in patients with heart failure and reduced ejection fraction across the disease severity,” said Javed Butler, MD, MPH, MBA, President of the Baylor Scott and White Research Institute and Professor of Medicine at University of Mississippi in Jackson, Mississippi.

    The positive benefit-risk profile of VERQUVO in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase 3 VICTORIA trial remains unchanged. In the U.S., VERQUVO is approved for the reduction of risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%.

    About VICTOR

    VICTOR (VerICiguaT in adults with ChrOnic heart failure and Reduced ejection fraction) (NCT05093933) was a randomized, double-blind, placebo-controlled, multicenter, event-driven Phase 3 study investigating the efficacy and safety of VERQUVO in adult patients with symptomatic chronic heart failure (New York Heart Association [NYHA] class II-IV) and a left ventricular ejection fraction (LVEF) of 40% or less. It enrolled 6,105 patients with chronic heart failure with reduced ejection fraction (HFrEF), who had not had a recent hospitalization for heart failure within 6 months or the need for outpatient intravenous diuretics within 3 months before randomization. Patients receiving contemporary guideline-directed medical therapy (GDMT), including SGLT2-inhibitors and angiotensin receptor-neprilysin inhibitor (ARNI), were randomized to receive either VERQUVO or placebo. VICTOR was the first large event-driven HFrEF trial performed in the contemporary era of quadruple foundational GDMT, in a compensated ambulatory heart failure population. Merck and Bayer AG are co-developers of the VICTOR trial. The study was executed by Merck.

    About VICTORIA

    VICTORIA (NCT02861534) was a randomized, placebo-controlled, parallel-group, multi-center, double-blind, Phase 3 study of VERQUVO versus placebo when given in combination with available heart failure therapies in patients with worsening chronic heart failure with reduced ejection fraction (HFrEF) following a decompensation event, defined as heart failure hospitalization or receiving an intravenous diuretic for heart failure without hospitalization. The primary endpoint of the study was the composite of time to first occurrence of cardiovascular death or heart failure hospitalization. Secondary endpoints included time to occurrence of cardiovascular death, time to first occurrence of heart failure hospitalization, time to total heart failure hospitalizations (including first and recurrent events), time to the composite of all-cause mortality or heart failure hospitalization, and time to all-cause mortality. The study enrolled 5,050 patients who were randomized to receive either VERQUVO once daily (titrated up to 10 mg) or placebo when given in combination with available heart failure therapies. The study, which was co-sponsored by Merck and Bayer, was conducted in collaboration with the Canadian VIGOUR Centre and the Duke Clinical Research Institute in more than 600 centers in 42 countries.

    About VERQUVO (vericiguat)

    VERQUVO is an oral once daily stimulator of soluble guanylate cyclase (sGC), an important enzyme in the nitric oxide (NO) signaling pathway. When NO binds to sGC, the enzyme catalyzes the synthesis of intracellular cyclic guanosine monophosphate (cGMP), a second messenger that plays a role in the regulation of vascular tone, cardiac contractility, and cardiac remodeling. Heart failure is associated with impaired synthesis of NO and decreased activity of sGC, which may contribute to myocardial and vascular dysfunction. By directly stimulating sGC, independently of and synergistically with NO, VERQUVO augments levels of intracellular cGMP, leading to smooth muscle relaxation and vasodilation.

    VERQUVO is FDA-approved to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

    Selected Safety Information for VERQUVO (vericiguat) tablets (2.5 mg, 5 mg, and 10 mg)

    WARNING: EMBRYO-FETAL TOXICITY

    Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.

    VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators. VERQUVO is contraindicated in pregnancy. Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose.

    In a clinical trial, the most commonly observed adverse events with VERQUVO vs placebo, occurring at a frequency greater than or equal to 5%, were hypotension (16% vs 15%) and anemia (10% vs 7%).

    Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended because of the potential for hypotension.

    There are no data on the presence of VERQUVO in human milk, the effects on the breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERQUVO, advise women not to breastfeed during treatment with VERQUVO.

    About Heart Failure with Reduced Ejection Fraction

    Heart failure with reduced ejection fraction (HFrEF), formerly known as systolic heart failure, is characterized by the compromised ability of the heart to pump blood sufficiently during its contraction phase. In the U.S., approximately 6.2 million adults (20 years of age and older) have heart failure, and approximately 50% of heart failure patients have HFrEF. An observational, cohort analysis of PINNACLE registry data showed that approximately half of patients with worsening chronic HFrEF are rehospitalized within 30 days of a worsening event, and an estimated one in five patients with worsening chronic HFrEF will die within two years.

    About the Worldwide Collaboration between Merck and Bayer

    Since October 2014, Bayer and Merck (known as MSD outside the U.S. and Canada) have pursued a worldwide collaboration in the field of sGC modulators. The collaboration brings together two leading companies that have stated their intent to fully evaluate this therapeutic class in areas of unmet medical need. The vericiguat program is being co-developed by Bayer and MSD. MSD has the commercial rights to vericiguat in the U.S. and Bayer has the exclusive commercial rights in the rest of world. The companies share equally the costs of the development of vericiguat.

    About Merck

    At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), LinkedIn and YouTube.

    Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

    This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

    Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

    The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

    Please see Prescribing Information, including Boxed Warning, for VERQUVO (vericiguat) at https://www.merck.com/product/usa/pi_circulars/v/verquvo/verquvo_pi.pdf and Medication Guide at https://www.merck.com/product/usa/pi_circulars/v/verquvo/verquvo_mg.pdf.


    Source: Merck & Co., Inc.

    Continue Reading

  • World of Warcraft patch 11.2 adds secret feature to skip delve content

    World of Warcraft patch 11.2 adds secret feature to skip delve content

    In World of Warcraft Patch 11.2, players can now bypass Delves with a hidden feature tied to the Reshii Wraps, drastically reducing the time needed to complete these instances. This secret function allows players to skip directly to the treasure room, cutting Delve runs down to just minutes.

    The update, released on August 5, introduced exciting new content, including the K’aresh zone, the Manaforge Omega raid, and a feature called Phase Diving. As part of the campaign, players can obtain the Reshii Wraps, a powerful artifact cloak with various abilities unlocked through Ethereal Strands.

    One of the cloak’s secret abilities, “Secrets of the Depths,” allows players to occasionally find Ethereal Portals within Delves. These portals can spawn randomly when interacting with a Flickergate, letting players skip all objectives and head straight to the treasure room. Once inside, players must complete a special task, such as defeating monsters or bosses in the Ethereal Routing Station. After completing the objective, they can exit and finish the Delve without further encounters.

    What’s more, the Nemesis Chest at the end of the Delve will be automatically maxed out, even if players bypass all the special Nemesis elite mobs in the instance. While the Ethereal Portals don’t appear every time, they provide a thrilling surprise, allowing players to complete Delves in as little as three minutes. Fans have praised this feature, with some enjoying the secret objectives, like fighting Zekvir and the Underpin, Nemeses from earlier WoW seasons.

    As World of Warcraft looks ahead to the Midnight expansion, it’s confirmed that 10 Delves will be available, along with a new companion and Nemesis. Whether future expansions will include more features like Ethereal Portals remains to be seen.

    Continue Reading